You Won't Believe the 5 Shocking RSV Trends of 2025 - #3 Will Leave You Speechless!

The landscape of respiratory syncytial virus (RSV) treatment saw significant advancements in 2025, particularly revolving around the efficacy of vaccinations for older adults and young children. New studies highlighted the profound impact these vaccines have had in reducing serious respiratory infections and fatalities among at-risk populations, including older adults and infants. Among the notable developments, the approval of two preventive treatments—nirsevimab and clesrovimab—offered promising new options for safeguarding against RSV during critical viral seasons.

The most compelling evidence comes from a study published in October 2025, which emphasized the importance of vaccinating adults aged 60 and older. This research used a multicohort Markov model to estimate the public health impact of the adjuvanted RSVPreF3 vaccine. The findings suggested that if 13.4 million older adults in the U.S. were to receive the vaccine, it could prevent over 700,000 cases of serious lower respiratory tract disease (LRTD) and 6,025 deaths over a five-year period stretching from August 2023 to July 2028. This aligns with updated vaccine recommendations issued in June 2024, designating that adults aged 75 and older, as well as those aged 60 to 74 with an increased risk for severe disease, should receive a single dose of an approved RSV vaccine.

Infants also notably benefited from advancements in RSV prevention. The long-acting monoclonal antibody nirsevimab, approved in July 2023, was evaluated in a study involving 409,723 infants born between February 1, 2024, and January 31, 2025. Findings revealed that nearly 47.5% of these infants received the antibody, leading to a hospitalization rate of just 0.4% among vaccinated infants. This stands in stark contrast to the 1.2% hospitalization rate amongst those who were not vaccinated, translating to a 71% to 77% reduction in RSV-associated hospitalizations.

The effectiveness of these preventive measures was further underlined when comparing hospitalization rates for infants aged 0 to 7 months during the 2024-2025 RSV season with those in the pre-COVID-19 pandemic years (2018-2020). According to the CDC’s Morbidity and Mortality Weekly Report, the total hospitalization rate for infants dropped significantly—from 11,681 cases during the 2018-2020 seasons to just 6,708 during the recent season. This decrease is attributed largely to the widespread use of the maternal RSV vaccine and nirsevimab.

Moreover, both nirsevimab and the RSV prefusion F vaccine, or RSVpreF, experienced high uptake among their target populations. A study reviewed data from 647 pregnant individuals eligible for the RSVpreF vaccine and found that 64% of them utilized the vaccine. Interestingly, factors such as older maternal age, having private insurance, and prior vaccination (e.g., against flu or COVID-19) correlated with higher uptake of the RSVpreF vaccine. However, about 40.4% of infants eligible for nirsevimab were born to parents who declined routine prenatal vaccines.

One of the most noteworthy approvals came in June 2025 with the FDA’s endorsement of clesrovimab (trademark name Enflonsia by Merck), which provides infants and neonates with a second immunization option to combat RSV. This approval was based on data from the phase 2b/3 CLEVER trial (NCT04767373), which showcased a 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% decrease in hospitalization rates. Dr. Octavio Ramilo, Chair of the Department of Infectious Diseases at St. Jude Children’s Research Hospital and trial investigator, emphasized the significance of this new intervention, stating that “Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV.”

As these studies and approvals illustrate, the landscape of RSV prevention is changing rapidly, offering hope to vulnerable populations. The focus on vaccination among both older adults and young children underscores the critical need for continued research and public health initiatives aimed at reducing the burden of this common but potentially deadly virus.